Back to Treatments

Treatment

Cabozantinib

1
Conditions
95
Trials
500
Participants
30%
Average Safety

Condition Evidence

Kidney cancer

95 trials · 500 participants

75% effectiveness · 30% safety
Cabozantinib | DFDA